{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-000899","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.359288+00:00","generated_at":"2026-06-19T18:09:07.847609+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Compass Therapeutics appoints David Wurzer to Board and as Audit Committee Chairman","bullets":["David Wurzer appointed as Class III director effective Feb 8, 2023.","Wurzer named Chairman of Audit Committee; independent and audit committee financial expert.","Compensation: $45,000 cash retainer plus $10,000 for Audit Chair; 50,000-share option award vesting over 4 years.","Wurzer is CFO of Enko Chem, Inc.; no family relationships or reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-000899","json":"https://secwatch.observer/filing/0001171843-23-000899.json","markdown":"https://secwatch.observer/filing/0001171843-23-000899.md","text":"https://secwatch.observer/filing/0001171843-23-000899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000899/0001171843-23-000899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000899/f8k_021023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T18:09:07.847609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7935f0e292","claim":"David Wurzer was appointed as Director at Compass Therapeutics, Inc..","evidence_excerpt":"On February 8, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000899/0001171843-23-000899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}